drugset / Trial / NCT01901328

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation

NCT01901328 ↗

Phase 3 Terminated 49 enrolled Merck & Co., Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of CB-5945 for the treatment of opioid-induced constipation (OIC)in adults taking opioid therapy for chronic non-cancer pain.

Timeline

Start
2013-04-07
Primary completion
2014-02-13
Completion
2014-02-13

Outcome

Outcome not reported

Stopped (Enrollment): “Sponsor decision due to lack of enrollment.”

Drugs

EvaluationDrugModalityDoseRoute
Subject bevenopran Small molecule 0.25 mg Oral